{"id":"NCT03341637","sponsor":"Takeda","briefTitle":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-14","primaryCompletion":"2019-01-26","completion":"2019-01-26","firstPosted":"2017-11-14","resultsPosted":"2019-08-15","lastUpdate":"2019-08-15"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dengue"],"interventions":[{"type":"BIOLOGICAL","name":"Tetravalent Dengue Vaccine (TDV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tetravalent Dengue Vaccine (TDV)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120","timeFrame":"One month post second dose (Day 120)","effectByArm":[{"arm":"Placebo","deltaMin":5.3,"sd":null},{"arm":"Tetravalent Dengue Vaccine (TDV)","deltaMin":327.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Mexico"]},"refs":{"pmids":["40099800","34131423"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["Viral upper respiratory tract infection","Nasopharyngitis","Viral pharyngitis","Pharyngitis","Pharyngitis bacterial"]}}